- |||||||||| Trial completion: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Oct 17, 2015
P=N/A, N=52, Completed, Active, not recruiting --> Completed | Initiation date: Nov 2010 --> Dec 2012 | Trial primary completion date: Sep 2015 --> Sep 2014 Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial primary completion date: Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) - Oct 15, 2015
P4, N=150, Completed, Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
- |||||||||| Trial termination, Trial primary completion date: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS (clinicaltrials.gov) - Oct 3, 2015
P2, N=12, Terminated, Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2015; 12 SCI volunteers completed the study. As the data analysis was negative, the decision was made not to proceed with MS recruitment.
- |||||||||| Trial termination: RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) - Sep 28, 2015
P3, N=74, Terminated, Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; in the absence of benefits and because of a statistically significant excess mortality in the group of patients receiving active stimulation.
- |||||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) - Sep 25, 2015 P4, N=90, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Apr 2016
- |||||||||| Trial primary completion date: Longitudinal Study of Outcomes Measures in ALS Trials (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=100, Active, not recruiting, Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| Enrollment closed, Trial primary completion date: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=150, Active, not recruiting, Trial primary completion date: Dec 2015 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016
- |||||||||| Trial primary completion date: Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=300, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2025
- |||||||||| Enrollment status, Enrollment change: Gastroesophageal Reflux Treatment in Scleroderma (clinicaltrials.gov) - Sep 21, 2015
P3, N=80, Recruiting, Recruiting --> Active, not recruiting Enrolling by invitation --> Recruiting | N=250 --> 80
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date, MRI: Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=0, Withdrawn, Initiation date: Apr 2013 --> Jul 2013 | Trial primary completion date: Apr 2014 --> Jan 2016 N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Apr 2015
- |||||||||| Enrollment closed, Trial primary completion date: Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=60, Active, not recruiting, N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- |||||||||| oxcarbazepine / Generic mfg.
Enrollment open, Trial initiation date: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Aug 24, 2015 P2, N=60, Recruiting, Active, not recruiting --> Suspended | Trial primary completion date: Oct 2014 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Oct 2014
|